AP3M2 is a core component of the AP-3 adaptor complex, a non-clathrin-associated protein trafficking machinery involved in vesicle budding from the Golgi and lysosomal targeting 1. The AP-3 complex facilitates anterograde axonal transport and synaptic vesicle recycling, functioning in concert with the BLOC-1 complex to direct cargo into neuronal vesicles destined for nerve terminals 2. Beyond its canonical neuronal role, AP3M2 has emerged as a significant prognostic biomarker in colorectal cancer, where elevated expression correlates with favorable overall survival and predicts chemotherapy responsiveness to oxaliplatin and 5-fluorouracil 1. Mechanistically, AP3M2 appears to regulate autophagy and reactive oxygen species levels in colorectal cancer cells; AP3M2 knockdown substantially reduces viability in multiple colorectal cancer cell lines (HCT-116, CACO2, HT29) 2. AP3M2 is also implicated in Alzheimer's disease pathophysiology, with knockdown reducing interleukin-6 levels in astrocytes 3. While AP3M2 knockout mice exhibit spontaneous epileptic seizures, genetic screening of epilepsy patients identified no pathogenic coding mutations, though regulatory variants remain potential disease candidates 4. Recent machine learning studies identified AP3M2 as part of diagnostic signatures for both colorectal cancer and heart failure-hepatocellular carcinoma comorbidity 5.